{"Symbol": "GILD", "AssetType": "Common Stock", "Name": "Gilead Sciences Inc", "Description": "Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.", "CIK": "882095", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "DRUG MANUFACTURERS - GENERAL", "Address": "333 LAKESIDE DRIVE, FOSTER CITY, CA, UNITED STATES, 94404", "OfficialSite": "https://www.gilead.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-12-31", "MarketCapitalization": "192280527000", "EBITDA": "14580999000", "PERatio": "22.89", "PEGRatio": "0.28", "BookValue": "18.23", "DividendPerShare": "3.16", "DividendYield": "0.0208", "EPS": "6.77", "RevenuePerShareTTM": "23.67", "ProfitMargin": "0.289", "OperatingMarginTTM": "0.374", "ReturnOnAssetsTTM": "0.125", "ReturnOnEquityTTM": "0.407", "RevenueTTM": "29443000000", "GrossProfitTTM": "23213001000", "DilutedEPSTTM": "6.77", "QuarterlyEarningsGrowthYOY": "0.235", "QuarterlyRevenueGrowthYOY": "0.047", "AnalystTargetPrice": "153.08", "AnalystRatingStrongBuy": "5", "AnalystRatingBuy": "17", "AnalystRatingHold": "6", "AnalystRatingSell": "0", "AnalystRatingStrongSell": "1", "TrailingPE": "22.89", "ForwardPE": "17.61", "PriceToSalesRatioTTM": "6.53", "PriceToBookRatio": "8.5", "EVToRevenue": "7.13", "EVToEBITDA": "19.4", "Beta": "0.387", "52WeekHigh": "157.29", "52WeekLow": "91.47", "50DayMovingAverage": "130.17", "200DayMovingAverage": "117.95", "SharesOutstanding": "1240680000", "SharesFloat": "1238270000", "PercentInsiders": "0.120", "PercentInstitutions": "92.300", "DividendDate": "2026-03-30", "ExDividendDate": "2026-03-13"}